What is Assembly Biosciences Return-on-Tangible-Asset?
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Assembly Biosciences's annualizedNet Income for the quarter that ended in Mar. 2025 was $-35.27 Mil. Assembly Biosciences's average total tangible assets for the quarter that ended in Mar. 2025 was $109.09 Mil. Therefore, Assembly Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -32.33%.
The historical rank and industry rank for Assembly Biosciences's Return-on-Tangible-Asset or its related term are showing as below:
ASMB'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -63.58 Med: -49.03 Max: -23.02
Current: -36.05
During the past 13 years, Assembly Biosciences's highest Return-on-Tangible-Asset was -23.02%. The lowest was -63.58%. And the median was -49.03%.
ASMB's Return-on-Tangible-Asset is ranked better than 50.93% of 1498
companies
in the Biotechnology industry
Industry Median: -37.355
vs ASMB: -36.05
Assembly Biosciences Return-on-Tangible-Asset Historical Data
The historical data trend for Assembly Biosciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Assembly Biosciences's Return-on-Tangible-Asset
For the Biotechnology subindustry, Assembly Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences's Return-on-Tangible-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2025) net income data.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Assembly Biosciences Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of Assembly Biosciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASMB has been successfully added to your 